Potential Targets Other Than PSMA for Prostate Cancer Theranostics: A Systematic Review
Background: Prostate-specific membrane antigen (PSMA) is not sufficiently overexpressed in a small proportion of prostate cancer (PCa) patients, who require other strategies for imaging and/or treatment. We reviewed potential targets other than PSMA for PCa theranostics in nuclear medicine that have...
Guardado en:
Autores principales: | Mathieu Gauthé, Paul Sargos, Eric Barret, Gaëlle Fromont-Hankard, Jean-Baptiste Beauval, Laurent Brureau, Gilles Créhange, Raphaële Renard-Penna, Charles Dariane, Gaëlle Fiard, Romain Mathieu, Guilhem Roubaud, Alain Ruffion, Morgan Rouprêt, Guillaume Ploussard, on behalf of the CC-AFU |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8988e2088a0847deb5a3abe8920cc3f5 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
PSMA expression by microvasculature of thyroid tumors – Potential implications for PSMA theranostics
por: Andrey Bychkov, et al.
Publicado: (2017) -
Spotlight on PSMA as a new theranostic biomarker for bladder cancer
por: Maria Maddalena Tumedei, et al.
Publicado: (2021) -
PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook
por: Maximilian A. Kirchner, et al.
Publicado: (2021) -
Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer
por: Kristin A. Plichta, et al.
Publicado: (2021) -
Deep Membrane Proteome Profiling Reveals Overexpression of Prostate-Specific Membrane Antigen (PSMA) in High-Risk Human Paraganglioma and Pheochromocytoma, Suggesting New Theranostic Opportunity
por: Ondrej Vit, et al.
Publicado: (2021)